Research and Markets (http://www.researchandmarkets.com/research/kh4r7g/us_skin_cancer) has announced the addition of the "US Skin Cancer Drug Pipeline Analysis" report to their offering.

The market for skin cancer in the US is expected to grow significantly owing to reasons like increasing number of patients and entry of new therapies which are in the pipeline. Additionally, the organic growth of key marketed drugs is also another major factor driving the growth in the US market. Of the different types of skin cancers in the US, Melanoma is the most common.

Though this segment accounts for just 5% of the overall US skin cancer market, it is a major factor causing 75% deaths in the region. Also, the US market witnesses a greater use of adjuvant therapy to treat early stage melanoma, as compared to the other regions.

With surgery being along with early detection is by far the most successful method of treating skin cancer in the US, the risk of recurrence in the patients is high. Additionally, the survival rates for the patients with advanced stages of the disease are very low. This has been a major challenge in the US market and companies investing in this space have been continuously researching on various options to improve the survival rates.

US Skin Cancer Drug Pipeline Analysis is comprehensive insight on the various drugs being developed for the treatment of skin cancer in US. Research report covers all drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the US skin cancer drug market based upon development process.

Following parameters for each drug profile in development phase are covered in -US Skin Cancer Drug Pipeline Analysis - research report:

- Drug Profile Overview

- Alternate Names for Drug

- Active Indication

- Phase of Development

- Mechanism of Action

- Brand Name

- Patent Information

- Orphan Designation by Indication, Country & Organisation

- Country for Clinical Trial

- Owner / Originator/ Licensee/Collaborator

- Administrative Route

- Drug Class

- ATC Codes

Number of Skin Cancer Drug in Pipeline by Clinical Phase:

- Research: 3

- Preclinical: 29

- Clinical: 5

- Phase 0: 1

- Phase-I: 29

- Phase-I/II: 18

- Phase-II: 41

- Phase-III: 13

- Registered: 4

- Marketed: 18

- Unknown: 1

Key Topics Covered:

1. US Skin Cancer Drug Market Overview

2. Skin Cancer Drug Clinical Phase: Unknown

3. Skin Cancer Drug Clinical Phase: Research

4. Skin Cancer Drug Clinical Phase: Preclinical

5. Skin Cancer Drug Clinical Phase: Clinical

6. Skin Cancer Drug Clinical Phase: Phase-0

7. Skin Cancer Drug Clinical Phase: Phase-I

8. Skin Cancer Drug Clinical Phase: Phase-I/II

9. Skin Cancer Drug Clinical Phase: Phase-II

10. Skin Cancer Drug Clinical Phase: Phase-III

11. Skin Cancer Drug Clinical Phase: Registered

12. Marketed

For more information visit http://www.researchandmarkets.com/research/kh4r7g/us_skin_cancer

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology